Please Wait a Moment
X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

04 Jan, 2022 | Return|

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

Updated Sample Acceptability Document

CTS was recently notified that one of the tubes listed in the Sample Acceptability document...

Read More >

Emailing Daily Shipment Schedules to CTS

CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...

Read More >

The FDA Guidance ZIKV video has been posted

The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

National Medical Laboratory Week from April 19th to April 25th

Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...

Read More >